NASHVILLE, TN, Mar 24, 2010 -- Smokefree Innotec, Inc. (PINKSHEETS: SFIO) (http://www.smokefree-innotec.com or http://www.realsmokefree.com) announced today that it has received strong feedback from retail in Belgium.
Smokefree Innotec, Inc. closed at $0.022 Wednesday, trading 1,625,629 shares.
Smokefree Innotec Reports Strong Solid Response From European Retail Convention
About Smokefree Innotec, Inc:
http://www.smokefree-innotec.com/
Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing a hi-tech, nicotine delivery cigarette-like device which is completely smoke and vapor-free and tobacco-free. Smokefree Innotec's products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking tobacco or similar substances is prohibited. Further, our products will allow the smoker to enjoy smoking while not having to worry about the offensive dangers and ill effects of regular cigarette smoking.
Free SFIO small cap stock news and charts available at http://stockprofiler.us/?action=main.stock_quotes&symbol=SFIO
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
DALLAS, March 25, 2010 -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration (KFDA) of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.
Access Pharmaceuticals, Inc. closed at $2.44 Wednesday, trading 34,239 shares.
Access Pharma's Korean Partner Gains Marketing Approval for MuGard
About Access
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
StockProfiler.US Announcement!
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://stockprofiler.us/index.php?action=main.register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------
Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com, http://www.fastmoneytalk.com, http://www.markettelegraph.com, http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://stockprofiler.us/?action=main.disclaimer
-------------------------------------------
Keywords: sfio, sfio stock, sfio stock news, sfio stock alerts, sfio company news, sfio small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news, small cap stock profile
Posts
No comments:
Post a Comment